These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21353541)

  • 21. Discovery of benzamides as potent human β3 adrenergic receptor agonists.
    Zhu C; Kar NF; Li B; Costa M; Dingley KH; Di Salvo J; Ha SN; Hurley AL; Li X; Miller RR; Salituro GM; Struthers M; Weber AE; Hale JJ; Edmondson SD
    Bioorg Med Chem Lett; 2016 Jan; 26(1):55-9. PubMed ID: 26590100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beta-3 adrenergic receptor agonists cause an increase in gastrointestinal transit time in wild-type mice, but not in mice lacking the beta-3 adrenergic receptor.
    Fletcher DS; Candelore MR; Grujic D; Lowell BB; Luell S; Susulic VS; Macintyre DE
    J Pharmacol Exp Ther; 1998 Nov; 287(2):720-4. PubMed ID: 9808702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular modeling of SWR-0342SA, a beta3-selective agonist, with beta1- and beta3-adrenoceptor.
    Ahmed M; Ishiguro M; Nagatomo T
    Life Sci; 2006 Mar; 78(17):2019-23. PubMed ID: 16310810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.
    Imanishi M; Nakajima Y; Tomishima Y; Hamashima H; Washizuka K; Sakurai M; Matsui S; Imamura E; Ueshima K; Yamamoto T; Yamamoto N; Ishikawa H; Nakano K; Unami N; Hamada K; Matsumura Y; Takamura F; Hattori K
    J Med Chem; 2008 Aug; 51(15):4804-22. PubMed ID: 18651730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced inhibition of L-type Ca2+ current by beta3-adrenergic stimulation in failing rat heart.
    Zhang ZS; Cheng HJ; Onishi K; Ohte N; Wannenburg T; Cheng CP
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1203-11. PubMed ID: 16135702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety.
    Sawa M; Mizuno K; Harada H; Tateishi H; Arai Y; Suzuki S; Oue M; Tsujiuchi H; Furutani Y; Kato S
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1061-4. PubMed ID: 15686912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of a novel and potent human and rat beta3-adrenergic receptor agonist, [3-[(2R)-[[(2R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yloxy]acetic acid.
    Harada H; Hirokawa Y; Suzuki K; Hiyama Y; Oue M; Kawashima H; Kato H; Yoshida N; Furutani Y; Kato S
    Chem Pharm Bull (Tokyo); 2005 Feb; 53(2):184-98. PubMed ID: 15684518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery.
    Topiol S; Sabio M
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1598-602. PubMed ID: 18243704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.
    Imanishi M; Itou S; Washizuka K; Hamashima H; Nakajima Y; Araki T; Tomishima Y; Sakurai M; Matsui S; Imamura E; Ueshima K; Yamamoto T; Yamamoto N; Ishikawa H; Nakano K; Unami N; Hamada K; Matsumura Y; Takamura F; Hattori K
    J Med Chem; 2008 Jul; 51(13):4002-20. PubMed ID: 18553954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent benzimidazolone based human beta(3)-adrenergic receptor agonists.
    Finley DR; Bell MG; Borel AG; Bloomquist WE; Cohen ML; Heiman ML; Kriauciunas A; Matthews DP; Miles T; Neel DA; Rito CJ; Sall DJ; Shuker AJ; Stephens TW; Tinsley FC; Winter MA; Jesudason CD
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5691-4. PubMed ID: 16931005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.
    Maruyama T; Seki N; Onda K; Suzuki T; Kawazoe S; Hayakawa M; Matsui T; Takasu T; Ohta M
    Bioorg Med Chem; 2009 Aug; 17(15):5510-9. PubMed ID: 19581100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.
    Huber T; Menon S; Sakmar TP
    Biochemistry; 2008 Oct; 47(42):11013-23. PubMed ID: 18821775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
    Diaz P; Phatak SS; Xu J; Astruc-Diaz F; Cavasotto CN; Naguib M
    J Med Chem; 2009 Jan; 52(2):433-44. PubMed ID: 19115816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists.
    Thompson SK; Washburn DG; Frazee JS; Madauss KP; Hoang TH; Lapinski L; Grygielko ET; Glace LE; Trizna W; Williams SP; Duraiswami C; Bray JD; Laping NJ
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4777-80. PubMed ID: 19595590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle.
    Fujimura T; Tamura K; Tsutsumi T; Yamamoto T; Nakamura K; Koibuchi Y; Kobayashi M; Yamaguchi O
    J Urol; 1999 Feb; 161(2):680-5. PubMed ID: 9915482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Species differences in the distribution of beta-adrenoceptor subtypes in bladder smooth muscle.
    Yamazaki Y; Takeda H; Akahane M; Igawa Y; Nishizawa O; Ajisawa Y
    Br J Pharmacol; 1998 Jun; 124(3):593-9. PubMed ID: 9647486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substituted 1,2,3,4-tetrahydroquinolin-6-yloxypropanes as beta3-adrenergic receptor agonists: design, synthesis, biological evaluation and pharmacophore modeling.
    Shakya N; Roy KK; Saxena AK
    Bioorg Med Chem; 2009 Jan; 17(2):830-47. PubMed ID: 19081260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
    Uehling DE; Shearer BG; Donaldson KH; Chao EY; Deaton DN; Adkison KK; Brown KK; Cariello NF; Faison WL; Lancaster ME; Lin J; Hart R; Milliken TO; Paulik MA; Sherman BW; Sugg EE; Cowan C
    J Med Chem; 2006 May; 49(9):2758-71. PubMed ID: 16640337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asymmetric synthesis of cis-2,5-disubstituted pyrrolidine, the core scaffold of β3-AR agonists.
    Xu F; Chung JY; Moore JC; Liu Z; Yoshikawa N; Hoerrner RS; Lee J; Royzen M; Cleator E; Gibson AG; Dunn R; Maloney KM; Alam M; Goodyear A; Lynch J; Yasuda N; Devine PN
    Org Lett; 2013 Mar; 15(6):1342-5. PubMed ID: 23451898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles.
    Goble SD; Wang L; Howell KL; Bansal A; Berger R; Brockunier L; DiSalvo J; Feighner S; Harper B; He J; Hurley A; Hreniuk D; Parmee E; Robbins M; Salituro G; Sanfiz A; Streckfuss E; Watkins E; Weber AE; Struthers M; Edmondson SD
    Bioorg Med Chem Lett; 2010 Mar; 20(6):1895-9. PubMed ID: 20181479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.